Advice
following a full submission
lanthanum carbonate (Fosrenol®) is not recommended for use within NHS Scotland.
Indication under review: as a phosphate binding agent for use in the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥1.78mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
When compared with placebo, in patients with chronic kidney disease not yet on dialysis, more patients treated with lanthanum carbonate achieved a serum phosphate concentration ≤1.49mmol/L.
The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
Download detailed advice116KB (PDF)
Medicine details
- Medicine name:
- lanthanum carbonate (Fosrenol)
- SMC ID:
- 640/10
- Indication:
- Control of hyperphosphataemia in adult patients with chronic renal failure not on dialysis with serum phosphate levels >1.78 mmol/1
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 October 2010